Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)

NCT02770885 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a medication called GLP-1 analogues can help reduce excessive fluid intake in adults with primary polydipsia.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 50 people

Who can join Ages 18+ · all sexes

Timeline Started 2016-03 · est. completion 2019-10

Where 1 site · Switzerland

What this study is testing ClinicalTrials.gov NCT02770885 ↗

Description as written by the study sponsor.

Glucagon like Peptide -1 (GLP-1) receptor agonists are well known to stimulate glucose-induced insulin secretion and to reduce energy intake. Recent findings from animal and human studies suggest a role of GLP-1 in regulating water and salt homeostasis. GLP-1 has been shown to reduce fluid intake after an oral salt load or during a meal - pointing to a hypodipsic effect. The aim of this study is to elucidate whether these putative hypodipsic properties of GLP-1 might be of advantage in persons with an exaggerated thirst perception as is the case in patients with primary polydipsia.

Treatments tested

Dulaglutide also known as Trulicity Drug

Treatment with dulaglutide for 3 weeks.
Placebo also known as Sodium Chloride 0.9% Drug

Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.

Main thing measured	Fluid intake in ml
Sponsor	University Hospital, Basel, Switzerland
Conditions studied	Primary Polydipsia
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02770885 ↗